{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:52:38Z","timestamp":1788382358357,"version":"build-2803163510"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005743","name":"Universit\u00e0 Cattolica del Sacro Cuore","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005743","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>To review current evidence on biologic therapies targeting type 2 inflammation in patients with eosinophilic COPD and respiratory comorbidities who remain uncontrolled despite optimized triple inhaled therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Recent phase 3 trials have shown that dupilumab provides the most consistent benefit in eosinophilic COPD, reducing exacerbations and improving lung function and quality of life. Mepolizumab has shown a more limited effect, mainly on exacerbation reduction, whereas benralizumab has not demonstrated clear clinical benefit. Blood eosinophil count remains the main biomarker for treatment selection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Biologic therapies are advancing precision medicine in COPD, with dupilumab currently showing the strongest overall evidence. Careful patient selection is essential. Broader phenotyping may further improve management, as comorbidities such as chronic rhinosinusitis may contribute to symptom burden and support a multidisciplinary approach. Future studies should clarify long-term outcomes and optimal biologic selection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11882-026-01271-8","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T06:36:23Z","timestamp":1776321383000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Beyond Triple Therapy: Anti-Type 2 Biologic Therapies for Eosinophilic COPD and Respiratory Comorbidities - a Review of Clinical Evidence"],"prefix":"10.1007","volume":"26","author":[{"given":"Pier-Valerio","family":"Mari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2538-1278","authenticated-orcid":false,"given":"Lorenzo","family":"Carriera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Ielo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loreta","family":"Di Michele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide Onofrio","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Selvaggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Gambacorta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Stivalini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Lipsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Baglioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Scala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"De Corso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Ojetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"1271_CR1","unstructured":"2026 GOLD Report and Pocket Guide. Global Initiative for Chronic Obstructive Lung Disease - GOLD [Internet]. [cited 2026 Feb 5]. Available from: https:\/\/goldcopd.org\/2026-gold-report-and-pocket-guide\/"},{"key":"1271_CR2","doi-asserted-by":"publisher","first-page":"101936","DOI":"10.1016\/j.eclinm.2023.101936","volume":"59","author":"Global burden of chronic respiratory diseases and risk factors","year":"2023","unstructured":"Global burden of chronic respiratory diseases and risk factors. 1990\u20132019: an update from the Global Burden of Disease Study 2019. eClinicalMedicine. 2023;59:101936. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101936.","journal-title":"eClinicalMedicine"},{"issue":"1","key":"1271_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2500\/aap.2015.36.3812","volume":"36","author":"SM May","year":"2015","unstructured":"May SM, Li JTC. Burden of chronic obstructive pulmonary disease: healthcare costs and beyond. Allergy Asthma Proc. 2015;36(1):4\u201310. https:\/\/doi.org\/10.2500\/aap.2015.36.3812.","journal-title":"Allergy Asthma Proc"},{"key":"1271_CR4","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.2147\/COPD.S163717","volume":"13","author":"S Chen","year":"2018","unstructured":"Chen S, Small M, Lindner L, Xu X. Symptomatic burden of COPD for patients receiving dual or triple therapy. Int J Chron Obstruct Pulmon Dis. 2018;13:1365\u201376. https:\/\/doi.org\/10.2147\/COPD.S163717.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"1271_CR5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12931-018-0944-3","volume":"19","author":"H Watz","year":"2018","unstructured":"Watz H, Tetzlaff K, Magnussen H, Mueller A, Rodriguez-Roisin R, Wouters EFM, et al. Spirometric changes during exacerbations of COPD: a post hoc analysis of the WISDOM trial. Respir Res. 2018;19(1):251. https:\/\/doi.org\/10.1186\/s12931-018-0944-3.","journal-title":"Respir Res"},{"issue":"10","key":"1271_CR6","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1136\/heartjnl-2023-323487","volume":"110","author":"NM Hawkins","year":"2024","unstructured":"Hawkins NM, Nordon C, Rhodes K, Talukdar M, McMullen S, Ekwaru P, et al. Heightened long-term cardiovascular risks after exacerbation of chronic obstructive pulmonary disease. Heart. 2024;110(10):702\u20139. https:\/\/doi.org\/10.1136\/heartjnl-2023-323487.","journal-title":"Heart"},{"key":"1271_CR7","doi-asserted-by":"publisher","first-page":"1404615","DOI":"10.3389\/fimmu.2024.1404615","volume":"15","author":"J Xu","year":"2024","unstructured":"Xu J, Zeng Q, Li S, Su Q, Fan H. Inflammation mechanism and research progress of COPD. Front Immunol. 2024;15:1404615. https:\/\/doi.org\/10.3389\/fimmu.2024.1404615.","journal-title":"Front Immunol"},{"issue":"1","key":"1271_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s41030-024-00280-0","volume":"11","author":"K Bartziokas","year":"2025","unstructured":"Bartziokas K, Papaioannou AI, Rovina N, Papaiakovou G, Loukides S, Steiropoulos P. \u0395osinophilic Chronic Obstructive Pulmonary Disease. What Do We Know So Far? Pulm Ther. 2025;11(1):7\u201324. https:\/\/doi.org\/10.1007\/s41030-024-00280-0.","journal-title":"What Do We Know So Far? Pulm Ther"},{"issue":"1","key":"1271_CR9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jaci.2016.05.011","volume":"138","author":"PJ Barnes","year":"2016","unstructured":"Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016;138(1):16\u201327. https:\/\/doi.org\/10.1016\/j.jaci.2016.05.011.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1271_CR10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1164\/rccm.201108-1553OC","volume":"186","author":"M Bafadhel","year":"2012","unstructured":"Bafadhel M, McKenna S, Terry S, Mistry V, Pancholi M, Venge P, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med. 2012;186(1):48\u201355. https:\/\/doi.org\/10.1164\/rccm.201108-1553OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"1271_CR11","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1136\/thoraxjnl-2015-207021","volume":"71","author":"ID Pavord","year":"2016","unstructured":"Pavord ID, Lettis S, Locantore N, Pascoe S, Jones PW, Wedzicha JA, et al. Blood eosinophils and inhaled corticosteroid\/long-acting \u03b2-2 agonist efficacy in COPD. Thorax. 2016;71(2):118\u201325. https:\/\/doi.org\/10.1136\/thoraxjnl-2015-207021.","journal-title":"Thorax"},{"issue":"6","key":"1271_CR12","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1183\/09031936.00162414","volume":"44","author":"D Singh","year":"2014","unstructured":"Singh D, Kolsum U, Brightling CE, Locantore N, Agusti A, Tal-Singer R, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014;44(6):1697\u2013700. https:\/\/doi.org\/10.1183\/09031936.00162414.","journal-title":"Eur Respir J"},{"issue":"5","key":"1271_CR13","doi-asserted-by":"publisher","first-page":"300060525134089","DOI":"10.1177\/03000605251340894","volume":"53","author":"S Colantuono","year":"2025","unstructured":"Colantuono S, Menzella F, Mari PV, Macagno F, Lombardi F, Baglivo I, et al. Patient response and remission in respiratory disease: Special focus on severe asthma and chronic obstructive pulmonary disease. J Int Med Res. 2025;53(5):3000605251340894. https:\/\/doi.org\/10.1177\/03000605251340894.","journal-title":"J Int Med Res"},{"issue":"11","key":"1271_CR14","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.3390\/jpm13111594","volume":"13","author":"L Carriera","year":"2023","unstructured":"Carriera L, Fant\u00f2 M, Martini A, D\u2019Abramo A, Puzio G, Scaramozzino MU, et al. Combination of Biological Therapy in Severe Asthma: Where We Are? J Pers Med. 2023;13(11):1594. https:\/\/doi.org\/10.3390\/jpm13111594.","journal-title":"J Pers Med"},{"key":"1271_CR15","doi-asserted-by":"publisher","unstructured":"Carriera L, Caporuscio S, Fant\u00f2 M, D\u2019Abramo A, Puzio G, Triolo L, et al. Combination treatment with monoclonal antibodies for the management of severe asthma and immune-mediated inflammatory diseases: a comprehensive review. Monaldi Arch Chest Dis. 2025;95(4). https:\/\/doi.org\/10.4081\/monaldi.2024.3079.","DOI":"10.4081\/monaldi.2024.3079"},{"key":"1271_CR16","doi-asserted-by":"publisher","DOI":"10.4081\/monaldi.2025.3319","author":"L Carriera","year":"2025","unstructured":"Carriera L, Mari PV, Barone R, Ielo S, Cataldo E, Di Tomasso M, et al. Potential novel role of asthma biologics as rescue therapy in the intensive care unit for life-threatening asthma exacerbations: a systematic review. Monaldi Arch Chest Dis. 2025. https:\/\/doi.org\/10.4081\/monaldi.2025.3319.","journal-title":"Monaldi Arch Chest Dis"},{"key":"1271_CR17","doi-asserted-by":"publisher","unstructured":"Mari PV, Coppola A, Cotesta D, Michele LD, Ricci A, Ojetti V. Lung Function Improvement Following COPD Exacerbation Under Dupilumab Therapy: A Case Report [Internet]. 2026. https:\/\/doi.org\/10.2174\/0115748855428216251121091639","DOI":"10.2174\/0115748855428216251121091639"},{"issue":"9","key":"1271_CR18","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41573-023-00750-1","volume":"22","author":"P Kolkhir","year":"2023","unstructured":"Kolkhir P, Akdis CA, Akdis M, Bachert C, Bieber T, Canonica GW, et al. Type 2 chronic inflammatory diseases: targets, therapies and unmet needs. Nat Rev Drug Discov. 2023;22(9):743\u201367. https:\/\/doi.org\/10.1038\/s41573-023-00750-1.","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"1271_CR19","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.bbadis.2011.06.002","volume":"1812","author":"E Mortaz","year":"2011","unstructured":"Mortaz E, Henricks PaJ, Kraneveld AD, Givi ME, Garssen J, Folkerts G. Cigarette smoke induces the release of CXCL-8 from human bronchial epithelial cells via TLRs and induction of the inflammasome. Biochim Biophys Acta. 2011;1812(9):1104\u201310. https:\/\/doi.org\/10.1016\/j.bbadis.2011.06.002.","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"1271_CR20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/mi.2013.77","volume":"7","author":"SD Pouwels","year":"2014","unstructured":"Pouwels SD, Heijink IH, ten Hacken NHT, Vandenabeele P, Krysko DV, Nawijn MC, et al. DAMPs activating innate and adaptive immune responses in COPD. Mucosal Immunol. 2014;7(2):215\u201326. https:\/\/doi.org\/10.1038\/mi.2013.77.","journal-title":"Mucosal Immunol"},{"issue":"1","key":"1271_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.immuni.2015.07.007","volume":"43","author":"H Hammad","year":"2015","unstructured":"Hammad H, Lambrecht BN. Barrier Epithelial Cells and the Control of Type 2 Immunity. Immunity. 2015;43(1):29\u201340. https:\/\/doi.org\/10.1016\/j.immuni.2015.07.007.","journal-title":"Immunity"},{"issue":"2","key":"1271_CR22","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1084\/jem.20062211","volume":"204","author":"Z Allakhverdi","year":"2007","unstructured":"Allakhverdi Z, Comeau MR, Jessup HK, Yoon BRP, Brewer A, Chartier S, et al. Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J Exp Med. 2007;204(2):253\u20138. https:\/\/doi.org\/10.1084\/jem.20062211.","journal-title":"J Exp Med"},{"issue":"4","key":"1271_CR23","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jaci.2025.01.017","volume":"155","author":"A Akenroye","year":"2025","unstructured":"Akenroye A, Boyce JA, Kita H. Targeting alarmins in asthma: From bench to clinic. J Allergy Clin Immunol. 2025;155(4):1133\u201348. https:\/\/doi.org\/10.1016\/j.jaci.2025.01.017.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"1271_CR24","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.immuni.2014.01.011","volume":"40","author":"TYF Halim","year":"2014","unstructured":"Halim TYF, Steer CA, Math\u00e4 L, Gold MJ, Martinez-Gonzalez I, McNagny KM, et al. Group 2 innate lymphoid cells are critical for the initiation of adaptive T helper 2 cell-mediated allergic lung inflammation. Immunity. 2014;40(3):425\u201335. https:\/\/doi.org\/10.1016\/j.immuni.2014.01.011.","journal-title":"Immunity"},{"issue":"9","key":"1271_CR25","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1084\/jem.20051135","volume":"202","author":"T Ito","year":"2005","unstructured":"Ito T, Wang YH, Duramad O, Hori T, Delespesse GJ, Watanabe N, et al. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J Exp Med. 2005;202(9):1213\u201323. https:\/\/doi.org\/10.1084\/jem.20051135.","journal-title":"J Exp Med"},{"key":"1271_CR26","doi-asserted-by":"publisher","first-page":"71","DOI":"10.12703\/r\/10-71","volume":"10","author":"AD Keegan","year":"2021","unstructured":"Keegan AD, Leonard WJ, Zhu J. Recent advances in understanding the role of IL-4 signaling. Fac Rev. 2021;10:71. https:\/\/doi.org\/10.12703\/r\/10-71.","journal-title":"Fac Rev"},{"key":"1271_CR27","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.2147\/DDDT.S150656","volume":"11","author":"C Pelaia","year":"2017","unstructured":"Pelaia C, Vatrella A, Busceti MT, Gallelli L, Terracciano R, Savino R, et al. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab. Drug Des Devel Ther. 2017;11:3137\u201344. https:\/\/doi.org\/10.2147\/DDDT.S150656.","journal-title":"Drug Des Devel Ther"},{"key":"1271_CR28","doi-asserted-by":"publisher","first-page":"851940","DOI":"10.3389\/fphar.2022.851940","volume":"13","author":"C Pelaia","year":"2022","unstructured":"Pelaia C, Heffler E, Crimi C, Maglio A, Vatrella A, Pelaia G, et al. Interleukins 4 and 13 in Asthma: Key Pathophysiologic Cytokines and Druggable Molecular Targets. Front Pharmacol. 2022;13:851940. https:\/\/doi.org\/10.3389\/fphar.2022.851940.","journal-title":"Front Pharmacol"},{"key":"1271_CR29","doi-asserted-by":"publisher","first-page":"1285598","DOI":"10.3389\/fimmu.2024.1285598","volume":"15","author":"S AlBloushi","year":"2024","unstructured":"AlBloushi S, Al-Ahmad M. Exploring the immunopathology of type 2 inflammatory airway diseases. Front Immunol. 2024;15:1285598. https:\/\/doi.org\/10.3389\/fimmu.2024.1285598.","journal-title":"Front Immunol"},{"issue":"1","key":"1271_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12931-019-1268-7","volume":"21","author":"TH Harries","year":"2020","unstructured":"Harries TH, Rowland V, Corrigan CJ, Marshall IJ, McDonnell L, Prasad V, et al. Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and meta-analysis. Respir Res. 2020;21(1):3. https:\/\/doi.org\/10.1186\/s12931-019-1268-7.","journal-title":"Respir Res"},{"issue":"6","key":"1271_CR31","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1016\/j.jaci.2018.04.010","volume":"141","author":"JH Yun","year":"2018","unstructured":"Yun JH, Lamb A, Chase R, Singh D, Parker MM, Saferali A, et al. Blood eosinophil thresholds and exacerbations in chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2018;141(6):2037\u2013e204710. https:\/\/doi.org\/10.1016\/j.jaci.2018.04.010.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1271_CR32","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3109\/15412550903499522","volume":"7","author":"EA Regan","year":"2010","unstructured":"Regan EA, Hokanson JE, Murphy JR, Make B, Lynch DA, Beaty TH, et al. Genetic epidemiology of COPD (COPDGene) study design. COPD. 2010;7(1):32\u201343. https:\/\/doi.org\/10.3109\/15412550903499522.","journal-title":"COPD"},{"issue":"1","key":"1271_CR33","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/1465-9921-11-122","volume":"11","author":"A Agusti","year":"2010","unstructured":"Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11(1):122. https:\/\/doi.org\/10.1186\/1465-9921-11-122.","journal-title":"Respir Res"},{"issue":"4","key":"1271_CR34","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1164\/rccm.201502-0235LE","volume":"192","author":"SH Siddiqui","year":"2015","unstructured":"Siddiqui SH, Guasconi A, Vestbo J, Jones P, Agusti A, Paggiaro P, et al. Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone\/Formoterol in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2015;192(4):523\u20135. https:\/\/doi.org\/10.1164\/rccm.201502-0235LE.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"1271_CR35","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.anai.2022.06.028","volume":"129","author":"Y \u00c7olak","year":"2022","unstructured":"\u00c7olak Y, Ingebrigtsen TS, Nordestgaard BG, Marott JL, Lange P, Vestbo J, et al. Plasma immunoglobulin E and risk of exacerbation and mortality in chronic obstructive pulmonary disease: A contemporary population-based cohort. Ann Allergy Asthma Immunol. 2022;129(4):490\u20136. https:\/\/doi.org\/10.1016\/j.anai.2022.06.028.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1271_CR36","doi-asserted-by":"publisher","first-page":"106879","DOI":"10.1016\/j.rmed.2022.106879","volume":"198","author":"I Ikwu","year":"2022","unstructured":"Ikwu I, Nicolas LG, Mehari A, Gillum RF. Fractional exhaled nitric oxide and mortality in asthma and chronic obstructive pulmonary disease in a national cohort aged 40 years and older. Respir Med. 2022;198:106879. https:\/\/doi.org\/10.1016\/j.rmed.2022.106879.","journal-title":"Respir Med"},{"key":"1271_CR37","doi-asserted-by":"publisher","first-page":"1648612","DOI":"10.3389\/fmed.2025.1648612","volume":"26","author":"R Zhou","year":"2025","unstructured":"Zhou R, Wang H, Zhang Y, Mai J, Yang L. Small airway disease as a key factor in COPD: new perspectives and insights. Front Med (Lausanne). 2025;26:12:1648612. https:\/\/doi.org\/10.3389\/fmed.2025.1648612.","journal-title":"Front Med (Lausanne)"},{"key":"1271_CR38","doi-asserted-by":"publisher","first-page":"8840594","DOI":"10.1155\/2023\/8840594","volume":"2023","author":"BK Shah","year":"2023","unstructured":"Shah BK, Singh B, Wang Y, Xie S, Wang C. Mucus Hypersecretion in Chronic Obstructive Pulmonary Disease and Its Treatment. Mediators Inflamm. 2023;2023:8840594. https:\/\/doi.org\/10.1155\/2023\/8840594.","journal-title":"Mediators Inflamm"},{"issue":"21","key":"1271_CR39","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1001\/jama.2023.2065","volume":"329","author":"AA Diaz","year":"2023","unstructured":"Diaz AA, Orejas JL, Grumley S, Nath HP, Wang W, Dolliver WR, et al. Airway-Occluding Mucus Plugs and Mortality in Patients With Chronic Obstructive Pulmonary Disease. JAMA. 2023;329(21):1832\u20139. https:\/\/doi.org\/10.1001\/jama.2023.2065.","journal-title":"JAMA"},{"issue":"6","key":"1271_CR40","doi-asserted-by":"publisher","first-page":"2401005","DOI":"10.1183\/13993003.01005-2024","volume":"64","author":"AA Diaz","year":"2024","unstructured":"Diaz AA, Grumley S, Yen A, Sonavane S, Elalami R, Abdalla M, et al. Eosinophils, mucus plugs and clinical outcomes: findings from two COPD cohorts. Eur Respir J. 2024;64(6):2401005. https:\/\/doi.org\/10.1183\/13993003.01005-2024.","journal-title":"Eur Respir J"},{"issue":"1","key":"1271_CR41","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.chest.2019.12.046","volume":"158","author":"Y Okajima","year":"2020","unstructured":"Okajima Y, Come CE, Nardelli P, Sonavane SK, Yen A, Nath HP, et al. Luminal Plugging on Chest CT Scan: Association With Lung Function, Quality of Life, and COPD Clinical Phenotypes. Chest. 2020;158(1):121\u201330. https:\/\/doi.org\/10.1016\/j.chest.2019.12.046.","journal-title":"Chest"},{"issue":"3","key":"1271_CR42","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S2213-2600(24)00362-X","volume":"13","author":"M Castro","year":"2025","unstructured":"Castro M, Papi A, Porsbjerg C, Lugogo NL, Brightling CE, Gonz\u00e1lez-Barcala FJ, et al. Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2025;13(3):208\u201320. https:\/\/doi.org\/10.1016\/S2213-2600(24)00362-X.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"1271_CR43","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/arm94020014","volume":"94","author":"L Carriera","year":"2026","unstructured":"Carriera L, Coppola A, Lipsi R, Baglioni S, Mari PV, Barone R, et al. Impact of Dupilumab on Small Airway Disease in Severe Asthma: A 12-Month Retrospective Real-World Study. Adv Respiratory Med. 2026;94(2):14. https:\/\/doi.org\/10.3390\/arm94020014.","journal-title":"Adv Respiratory Med"},{"issue":"2","key":"1271_CR44","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jaip.2025.10.015","volume":"14","author":"R Campisi","year":"2026","unstructured":"Campisi R, Nolasco S, Bonsignore M, Nardo AA, Intravaia R, Pelaia C, et al. Effectiveness of Mepolizumab on Mucus Plug Reduction and Clinical Outcomes in Severe Eosinophilic Asthma: A Prospective Observational Study. J Allergy Clin Immunology: Pract. 2026;14(2):404\u2013e4141. https:\/\/doi.org\/10.1016\/j.jaip.2025.10.015.","journal-title":"J Allergy Clin Immunology: Pract"},{"issue":"8","key":"1271_CR45","doi-asserted-by":"publisher","first-page":"e13899","DOI":"10.1111\/cts.13899","volume":"17","author":"MR McCann","year":"2024","unstructured":"McCann MR, Kosloski MP, Xu C, Davis JD, Kamal MA, Dupilumab. Mechanism of action, clinical, and translational science. Clin Transl Sci. 2024;17(8):e13899. https:\/\/doi.org\/10.1111\/cts.13899.","journal-title":"Clin Transl Sci"},{"issue":"3","key":"1271_CR46","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2303951","volume":"389","author":"SP Bhatt","year":"2023","unstructured":"Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Cole J, Bafadhel M, et al. Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts. N Engl J Med. 2023;389(3):205\u201314. https:\/\/doi.org\/10.1056\/NEJMoa2303951.","journal-title":"N Engl J Med"},{"issue":"24","key":"1271_CR47","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1056\/NEJMoa2401304","volume":"390","author":"SP Bhatt","year":"2024","unstructured":"Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, et al. Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation. N Engl J Med. 2024;390(24):2274\u201383. https:\/\/doi.org\/10.1056\/NEJMoa2401304.","journal-title":"N Engl J Med"},{"issue":"3","key":"1271_CR48","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S2213-2600(24)00409-0","volume":"13","author":"SP Bhatt","year":"2025","unstructured":"Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, et al. Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2025;13(3):234\u201343. https:\/\/doi.org\/10.1016\/S2213-2600(24)00409-0.","journal-title":"Lancet Respir Med"},{"issue":"4","key":"1271_CR49","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2165\/11584340-000000000-00000","volume":"50","author":"DA Smith","year":"2011","unstructured":"Smith DA, Minthorn EA, Beerahee M. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody. Clin Pharmacokinet. 2011;50(4):215\u201327. https:\/\/doi.org\/10.2165\/11584340-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"issue":"17","key":"1271_CR50","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","volume":"377","author":"ID Pavord","year":"2017","unstructured":"Pavord ID, Chanez P, Criner GJ, Kerstjens HAM, Korn S, Lugogo N, et al. Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease. N Engl J Med. 2017;377(17):1613\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1708208.","journal-title":"N Engl J Med"},{"issue":"17","key":"1271_CR51","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1056\/NEJMoa2413181","volume":"392","author":"FC Sciurba","year":"2025","unstructured":"Sciurba FC, Criner GJ, Christenson SA, Martinez FJ, Papi A, Roche N, et al. Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype. N Engl J Med. 2025;392(17):1710\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2413181.","journal-title":"N Engl J Med"},{"key":"1271_CR52","doi-asserted-by":"publisher","first-page":"4839230","DOI":"10.1155\/2018\/4839230","volume":"2018","author":"C Pelaia","year":"2018","unstructured":"Pelaia C, Calabrese C, Vatrella A, Busceti MT, Garofalo E, Lombardo N, et al. Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma. Biomed Res Int. 2018;2018:4839230. https:\/\/doi.org\/10.1155\/2018\/4839230.","journal-title":"Biomed Res Int"},{"issue":"11","key":"1271_CR53","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMoa1905248","volume":"381","author":"GJ Criner","year":"2019","unstructured":"Criner GJ, Celli BR, Brightling CE, Agusti A, Papi A, Singh D, et al. Benralizumab for the Prevention of COPD Exacerbations. N Engl J Med. 2019;381(11):1023\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1905248.","journal-title":"N Engl J Med"},{"key":"1271_CR54","unstructured":"Update on the RESOLUTE Phase III. trial for Fasenra in chronic obstructive pulmonary disease [Internet]. 2025 [cited 2026 Feb 8]. Available from: https:\/\/www.astrazeneca.com\/content\/astraz\/media-centre\/press-releases\/2025\/update-on-resolute-phase-iii-trial.html"},{"issue":"1","key":"1271_CR55","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s12931-024-02998-6","volume":"25","author":"M Caminati","year":"2024","unstructured":"Caminati M, Vatrella A, Rogliani P, Carpagnano E, Spanevello A, Senna G. Tezepelumab for severe asthma: elevating current practice to recognize epithelial driven profiles. Respir Res. 2024;25(1):367. https:\/\/doi.org\/10.1186\/s12931-024-02998-6.","journal-title":"Respir Res"},{"issue":"1","key":"1271_CR56","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S2213-2600(24)00324-2","volume":"13","author":"D Singh","year":"2025","unstructured":"Singh D, Brightling CE, Rabe KF, Han MK, Christenson SA, Drummond MB, et al. Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial. Lancet Respir Med. 2025;13(1):47\u201358. https:\/\/doi.org\/10.1016\/S2213-2600(24)00324-2.","journal-title":"Lancet Respir Med"},{"issue":"6","key":"1271_CR57","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1016\/j.jaci.2024.12.1086","volume":"155","author":"D Singh","year":"2025","unstructured":"Singh D, Han MK, Llanos JP, Martin N, Parulekar A, Kostikas K, et al. Clarification of the efficacy of tezepelumab in the phase 2a COURSE trial. J Allergy Clin Immunol. 2025;155(6):2084\u20135. https:\/\/doi.org\/10.1016\/j.jaci.2024.12.1086.","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"1271_CR58","doi-asserted-by":"publisher","first-page":"4379","DOI":"10.21037\/jtd-2025-769","volume":"17","author":"D Afrose","year":"2025","unstructured":"Afrose D, Valizadeh M, Sivapalan P. Exacerbation control in chronic obstructive pulmonary disease with tezepelumab: insights from the COURSE trial. J Thorac Dis. 2025;17(7):4379\u201382. https:\/\/doi.org\/10.21037\/jtd-2025-769.","journal-title":"J Thorac Dis"},{"key":"1271_CR59","unstructured":"Randomised AZA. Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease [Clinical trial registration] [Internet]. clinicaltrials.gov; 2026 [cited 2026 Feb 8]. Report: NCT06883305. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06883305"},{"issue":"5","key":"1271_CR60","doi-asserted-by":"publisher","first-page":"00718","DOI":"10.1183\/23120541.00718-2023","volume":"10","author":"KF Rabe","year":"2024","unstructured":"Rabe KF, Martinez FJ, Bhatt SP, Kawayama T, Cosio BG, Mroz RM, et al. AERIFY-1\/2: two phase 3, randomised, controlled trials of itepekimab in former smokers with moderate-to-severe COPD. ERJ Open Res. 2024;10(5):00718\u20132023. https:\/\/doi.org\/10.1183\/23120541.00718-2023.","journal-title":"ERJ Open Res"},{"issue":"1","key":"1271_CR61","doi-asserted-by":"publisher","first-page":"2402231","DOI":"10.1183\/13993003.02231-2024","volume":"66","author":"D Singh","year":"2025","unstructured":"Singh D, Guller P, Reid F, Doffman S, Sepp\u00e4l\u00e4 U, Psallidas I, et al. A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4. Eur Respir J. 2025;66(1):2402231. https:\/\/doi.org\/10.1183\/13993003.02231-2024.","journal-title":"Eur Respir J"},{"key":"1271_CR62","unstructured":"Phase AZA, Multicentre III. Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations (OBERON) [Clinical trial registration] [Internet]. clinicaltrials.gov; 2026 Jan [cited 2026 Feb 8]. Report: NCT05166889. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05166889"},{"key":"1271_CR63","unstructured":"Phase AZA, Multicentre III. Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations (TITANIA) [Clinical trial registration] [Internet]. clinicaltrials.gov; 2026 Jan [cited 2026 Feb 8]. Report: NCT05158387. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05158387"},{"key":"1271_CR64","unstructured":"Phase AZA, Multicentre III. Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) With a History of Exacerbations (PROSPERO). [Clinical trial registration] [Internet]. clinicaltrials.gov; 2026 Jan [cited 2026 Feb 8]. Report: NCT05742802. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05742802"},{"issue":"5","key":"1271_CR65","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S2213-2600(21)00556-7","volume":"10","author":"AJ Yousuf","year":"2022","unstructured":"Yousuf AJ, Mohammed S, Carr L, Yavari Ramsheh M, Micieli C, Mistry V, et al. Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial. Lancet Respir Med. 2022;10(5):469\u201377. https:\/\/doi.org\/10.1016\/S2213-2600(21)00556-7.","journal-title":"Lancet Respir Med"},{"key":"1271_CR66","doi-asserted-by":"publisher","unstructured":"Greening N, Brightling CE, Tal-Singer R, Celli B, Agust\u00ed \u00c0, Korn S, et al. Late Breaking Abstract - Randomised, placebo-controlled trial of astegolimab for COPD with frequent exacerbations: ALIENTO. Eur Respir J. 2025;66(suppl 69). https:\/\/doi.org\/10.1183\/13993003.congress-2025.RCT1116.","DOI":"10.1183\/13993003.congress-2025.RCT1116"},{"key":"1271_CR67","unstructured":"Astegolimab Meets Endpoint in One COPD Trial. Misses in Another - Pulmonology Advisor [Internet]. [cited 2026 Feb 8]. Available from: https:\/\/www.pulmonologyadvisor.com\/news\/astegolimab-meets-endpoint-in-one-copd-trial-misses-in-another\/"},{"key":"1271_CR68","unstructured":"Hoffmann-La Roche A, Phase II, Randomized, Double-Blind. Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations [Clinical trial registration] [Internet]. clinicaltrials.gov; 2017 Sep [cited 2026 Feb 8]. Report: NCT02546700. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02546700"},{"key":"1271_CR69","doi-asserted-by":"publisher","first-page":"108333","DOI":"10.1016\/j.rmed.2025.108333","volume":"248","author":"M Cazzola","year":"2025","unstructured":"Cazzola M, Hanania NA, Rogliani P. Comorbidities as treatable traits of chronic airway diseases. Respir Med. 2025;248:108333. https:\/\/doi.org\/10.1016\/j.rmed.2025.108333.","journal-title":"Respir Med"},{"issue":"5","key":"1271_CR70","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1183\/09031936.00119712","volume":"42","author":"K H\u00e5kansson","year":"2013","unstructured":"H\u00e5kansson K, Konge L, Thomsen SF, Backer V, von Buchwald C. Sinonasal inflammation in COPD: a systematic review. Eur Respir J. 2013;42(5):1402\u201311. https:\/\/doi.org\/10.1183\/09031936.00119712.","journal-title":"Eur Respir J"},{"issue":"4","key":"1271_CR71","doi-asserted-by":"publisher","first-page":"333","DOI":"10.12932\/AP-240724-1896","volume":"42","author":"Y Kluanwan","year":"2024","unstructured":"Kluanwan Y, Pinyopornpanish K, Yan C, Bunupuradah T, Sanchat T. Chronic rhinitis and its impact on COPD: A literature review. Asian Pac J Allergy Immunol. 2024;42(4):333\u201340. https:\/\/doi.org\/10.12932\/AP-240724-1896.","journal-title":"Asian Pac J Allergy Immunol"},{"key":"1271_CR72","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2147\/COPD.S493219","volume":"20","author":"A Andersson","year":"2025","unstructured":"Andersson A, Bergqvist J, Schi\u00f6ler L, Bossios A, Farnebo L, Holmlund T, et al. Chronic Airflow Limitation, Lower Respiratory Symptoms, COPD and Chronic Rhinosinusitis in a Middle-Aged Population: The Swedish CArdioPulmonary bioImage Study (SCAPIS). A Link Between the Lower and Upper Airways. Int J Chron Obstruct Pulmon Dis. 2025;20:273\u201386. https:\/\/doi.org\/10.2147\/COPD.S493219.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1271_CR73","doi-asserted-by":"publisher","first-page":"106092","DOI":"10.1016\/j.rmed.2020.106092","volume":"171","author":"E Arndal","year":"2020","unstructured":"Arndal E, S\u00f8rensen AL, Lapperre TS, Said N, Trampedach C, Aan\u00e6s K, et al. Chronic rhinosinusitis in COPD: A prevalent but unrecognized comorbidity impacting health related quality of life. Respir Med. 2020;171:106092. https:\/\/doi.org\/10.1016\/j.rmed.2020.106092.","journal-title":"Respir Med"},{"issue":"1","key":"1271_CR74","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3109\/15412555.2010.540272","volume":"8","author":"A Kelemence","year":"2011","unstructured":"Kelemence A, Abadoglu O, Gumus C, Berk S, Epozturk K, Akkurt I. The frequency of chronic rhinosinusitis\/nasal polyp in COPD and its effect on the severity of COPD. COPD. 2011;8(1):8\u201312. https:\/\/doi.org\/10.3109\/15412555.2010.540272.","journal-title":"COPD"},{"issue":"1","key":"1271_CR75","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jaip.2018.06.029","volume":"7","author":"U Singh","year":"2019","unstructured":"Singh U, Wangia-Anderson V, Bernstein JA. Chronic Rhinitis Is a High-Risk Comorbidity for 30-Day Hospital Readmission of Patients with Asthma and Chronic Obstructive Pulmonary Disease. J Allergy Clin Immunol Pract. 2019;7(1):279\u2013e2856. https:\/\/doi.org\/10.1016\/j.jaip.2018.06.029.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"1271_CR76","doi-asserted-by":"publisher","first-page":"00184","DOI":"10.1183\/23120541.00184-2021","volume":"7","author":"N Obling","year":"2021","unstructured":"Obling N, Backer V, Hurst JR, Bodtger U. Upper airway symptoms associate with the eosinophilic phenotype of COPD. ERJ Open Res. 2021;7(3):00184\u20132021. https:\/\/doi.org\/10.1183\/23120541.00184-2021.","journal-title":"ERJ Open Res"},{"issue":"2","key":"1271_CR77","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1183\/13993003.01359-2015","volume":"47","author":"A Agusti","year":"2016","unstructured":"Agusti A, Bel E, Thomas M, Vogelmeier C, Brusselle G, Holgate S, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. 2016;47(2):410\u20139. https:\/\/doi.org\/10.1183\/13993003.01359-2015.","journal-title":"Eur Respir J"},{"issue":"3","key":"1271_CR78","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1056\/NEJMe2305752","volume":"389","author":"A Agusti","year":"2023","unstructured":"Agusti A. Biologics for COPD \u2014 Finally Here. N Engl J Med. 2023;389(3):274\u20135. https:\/\/doi.org\/10.1056\/NEJMe2305752.","journal-title":"N Engl J Med"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-026-01271-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11882-026-01271-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-026-01271-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:09:08Z","timestamp":1781647748000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11882-026-01271-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1271"],"URL":"https:\/\/doi.org\/10.1007\/s11882-026-01271-8","relation":{},"ISSN":["1534-6315"],"issn-type":[{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"25 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29"}}